Research ArticleArticle
The Role of Aldehyde Oxidase and Xanthine Oxidase in the Biotransformation of a Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5
Ryan D. Morrison, Anna L. Blobaum, Frank W. Byers, Tammy S. Santomango, Thomas M. Bridges, Donald Stec, Katrina A. Brewer, Raymundo Sanchez-Ponce, Melany M. Corlew, Roger Rush, Andrew S. Felts, Jason Manka, Brittney S. Bates, Daryl F. Venable, Alice L. Rodriguez, Carrie K. Jones, Colleen M. Niswender, P. Jeffrey Conn, Craig W. Lindsley, Kyle A. Emmitte and J. Scott Daniels
Drug Metabolism and Disposition September 2012, 40 (9) 1834-1845; DOI: https://doi.org/10.1124/dmd.112.046136
Ryan D. Morrison
Drug Metabolism and Pharmacokinetics (R.D.M., A.L.B., F.W.B., T.S.S., T.M.B., K.A.B., J.S.D.), Medicinal Chemistry (A.S.F., J.M., B.S.B., C.W.L., K.A.E.), Molecular Pharmacology (D.F.V., A.L.R., C.M.N., P.J.C.), and Behavioral Pharmacology (C.K.J.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Chemistry, Vanderbilt University, Nashville, Tennessee (D.S.); and Preclinical Development (R.S.-P., M.M.C., R.R.), Seaside Therapeutics, Inc., Cambridge, Massachusetts
Anna L. Blobaum
Drug Metabolism and Pharmacokinetics (R.D.M., A.L.B., F.W.B., T.S.S., T.M.B., K.A.B., J.S.D.), Medicinal Chemistry (A.S.F., J.M., B.S.B., C.W.L., K.A.E.), Molecular Pharmacology (D.F.V., A.L.R., C.M.N., P.J.C.), and Behavioral Pharmacology (C.K.J.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Chemistry, Vanderbilt University, Nashville, Tennessee (D.S.); and Preclinical Development (R.S.-P., M.M.C., R.R.), Seaside Therapeutics, Inc., Cambridge, Massachusetts
Frank W. Byers
Drug Metabolism and Pharmacokinetics (R.D.M., A.L.B., F.W.B., T.S.S., T.M.B., K.A.B., J.S.D.), Medicinal Chemistry (A.S.F., J.M., B.S.B., C.W.L., K.A.E.), Molecular Pharmacology (D.F.V., A.L.R., C.M.N., P.J.C.), and Behavioral Pharmacology (C.K.J.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Chemistry, Vanderbilt University, Nashville, Tennessee (D.S.); and Preclinical Development (R.S.-P., M.M.C., R.R.), Seaside Therapeutics, Inc., Cambridge, Massachusetts
Tammy S. Santomango
Drug Metabolism and Pharmacokinetics (R.D.M., A.L.B., F.W.B., T.S.S., T.M.B., K.A.B., J.S.D.), Medicinal Chemistry (A.S.F., J.M., B.S.B., C.W.L., K.A.E.), Molecular Pharmacology (D.F.V., A.L.R., C.M.N., P.J.C.), and Behavioral Pharmacology (C.K.J.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Chemistry, Vanderbilt University, Nashville, Tennessee (D.S.); and Preclinical Development (R.S.-P., M.M.C., R.R.), Seaside Therapeutics, Inc., Cambridge, Massachusetts
Thomas M. Bridges
Drug Metabolism and Pharmacokinetics (R.D.M., A.L.B., F.W.B., T.S.S., T.M.B., K.A.B., J.S.D.), Medicinal Chemistry (A.S.F., J.M., B.S.B., C.W.L., K.A.E.), Molecular Pharmacology (D.F.V., A.L.R., C.M.N., P.J.C.), and Behavioral Pharmacology (C.K.J.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Chemistry, Vanderbilt University, Nashville, Tennessee (D.S.); and Preclinical Development (R.S.-P., M.M.C., R.R.), Seaside Therapeutics, Inc., Cambridge, Massachusetts
Donald Stec
Drug Metabolism and Pharmacokinetics (R.D.M., A.L.B., F.W.B., T.S.S., T.M.B., K.A.B., J.S.D.), Medicinal Chemistry (A.S.F., J.M., B.S.B., C.W.L., K.A.E.), Molecular Pharmacology (D.F.V., A.L.R., C.M.N., P.J.C.), and Behavioral Pharmacology (C.K.J.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Chemistry, Vanderbilt University, Nashville, Tennessee (D.S.); and Preclinical Development (R.S.-P., M.M.C., R.R.), Seaside Therapeutics, Inc., Cambridge, Massachusetts
Katrina A. Brewer
Drug Metabolism and Pharmacokinetics (R.D.M., A.L.B., F.W.B., T.S.S., T.M.B., K.A.B., J.S.D.), Medicinal Chemistry (A.S.F., J.M., B.S.B., C.W.L., K.A.E.), Molecular Pharmacology (D.F.V., A.L.R., C.M.N., P.J.C.), and Behavioral Pharmacology (C.K.J.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Chemistry, Vanderbilt University, Nashville, Tennessee (D.S.); and Preclinical Development (R.S.-P., M.M.C., R.R.), Seaside Therapeutics, Inc., Cambridge, Massachusetts
Raymundo Sanchez-Ponce
Drug Metabolism and Pharmacokinetics (R.D.M., A.L.B., F.W.B., T.S.S., T.M.B., K.A.B., J.S.D.), Medicinal Chemistry (A.S.F., J.M., B.S.B., C.W.L., K.A.E.), Molecular Pharmacology (D.F.V., A.L.R., C.M.N., P.J.C.), and Behavioral Pharmacology (C.K.J.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Chemistry, Vanderbilt University, Nashville, Tennessee (D.S.); and Preclinical Development (R.S.-P., M.M.C., R.R.), Seaside Therapeutics, Inc., Cambridge, Massachusetts
Melany M. Corlew
Drug Metabolism and Pharmacokinetics (R.D.M., A.L.B., F.W.B., T.S.S., T.M.B., K.A.B., J.S.D.), Medicinal Chemistry (A.S.F., J.M., B.S.B., C.W.L., K.A.E.), Molecular Pharmacology (D.F.V., A.L.R., C.M.N., P.J.C.), and Behavioral Pharmacology (C.K.J.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Chemistry, Vanderbilt University, Nashville, Tennessee (D.S.); and Preclinical Development (R.S.-P., M.M.C., R.R.), Seaside Therapeutics, Inc., Cambridge, Massachusetts
Roger Rush
Drug Metabolism and Pharmacokinetics (R.D.M., A.L.B., F.W.B., T.S.S., T.M.B., K.A.B., J.S.D.), Medicinal Chemistry (A.S.F., J.M., B.S.B., C.W.L., K.A.E.), Molecular Pharmacology (D.F.V., A.L.R., C.M.N., P.J.C.), and Behavioral Pharmacology (C.K.J.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Chemistry, Vanderbilt University, Nashville, Tennessee (D.S.); and Preclinical Development (R.S.-P., M.M.C., R.R.), Seaside Therapeutics, Inc., Cambridge, Massachusetts
Andrew S. Felts
Drug Metabolism and Pharmacokinetics (R.D.M., A.L.B., F.W.B., T.S.S., T.M.B., K.A.B., J.S.D.), Medicinal Chemistry (A.S.F., J.M., B.S.B., C.W.L., K.A.E.), Molecular Pharmacology (D.F.V., A.L.R., C.M.N., P.J.C.), and Behavioral Pharmacology (C.K.J.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Chemistry, Vanderbilt University, Nashville, Tennessee (D.S.); and Preclinical Development (R.S.-P., M.M.C., R.R.), Seaside Therapeutics, Inc., Cambridge, Massachusetts
Jason Manka
Drug Metabolism and Pharmacokinetics (R.D.M., A.L.B., F.W.B., T.S.S., T.M.B., K.A.B., J.S.D.), Medicinal Chemistry (A.S.F., J.M., B.S.B., C.W.L., K.A.E.), Molecular Pharmacology (D.F.V., A.L.R., C.M.N., P.J.C.), and Behavioral Pharmacology (C.K.J.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Chemistry, Vanderbilt University, Nashville, Tennessee (D.S.); and Preclinical Development (R.S.-P., M.M.C., R.R.), Seaside Therapeutics, Inc., Cambridge, Massachusetts
Brittney S. Bates
Drug Metabolism and Pharmacokinetics (R.D.M., A.L.B., F.W.B., T.S.S., T.M.B., K.A.B., J.S.D.), Medicinal Chemistry (A.S.F., J.M., B.S.B., C.W.L., K.A.E.), Molecular Pharmacology (D.F.V., A.L.R., C.M.N., P.J.C.), and Behavioral Pharmacology (C.K.J.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Chemistry, Vanderbilt University, Nashville, Tennessee (D.S.); and Preclinical Development (R.S.-P., M.M.C., R.R.), Seaside Therapeutics, Inc., Cambridge, Massachusetts
Daryl F. Venable
Drug Metabolism and Pharmacokinetics (R.D.M., A.L.B., F.W.B., T.S.S., T.M.B., K.A.B., J.S.D.), Medicinal Chemistry (A.S.F., J.M., B.S.B., C.W.L., K.A.E.), Molecular Pharmacology (D.F.V., A.L.R., C.M.N., P.J.C.), and Behavioral Pharmacology (C.K.J.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Chemistry, Vanderbilt University, Nashville, Tennessee (D.S.); and Preclinical Development (R.S.-P., M.M.C., R.R.), Seaside Therapeutics, Inc., Cambridge, Massachusetts
Alice L. Rodriguez
Drug Metabolism and Pharmacokinetics (R.D.M., A.L.B., F.W.B., T.S.S., T.M.B., K.A.B., J.S.D.), Medicinal Chemistry (A.S.F., J.M., B.S.B., C.W.L., K.A.E.), Molecular Pharmacology (D.F.V., A.L.R., C.M.N., P.J.C.), and Behavioral Pharmacology (C.K.J.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Chemistry, Vanderbilt University, Nashville, Tennessee (D.S.); and Preclinical Development (R.S.-P., M.M.C., R.R.), Seaside Therapeutics, Inc., Cambridge, Massachusetts
Carrie K. Jones
Drug Metabolism and Pharmacokinetics (R.D.M., A.L.B., F.W.B., T.S.S., T.M.B., K.A.B., J.S.D.), Medicinal Chemistry (A.S.F., J.M., B.S.B., C.W.L., K.A.E.), Molecular Pharmacology (D.F.V., A.L.R., C.M.N., P.J.C.), and Behavioral Pharmacology (C.K.J.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Chemistry, Vanderbilt University, Nashville, Tennessee (D.S.); and Preclinical Development (R.S.-P., M.M.C., R.R.), Seaside Therapeutics, Inc., Cambridge, Massachusetts
Colleen M. Niswender
Drug Metabolism and Pharmacokinetics (R.D.M., A.L.B., F.W.B., T.S.S., T.M.B., K.A.B., J.S.D.), Medicinal Chemistry (A.S.F., J.M., B.S.B., C.W.L., K.A.E.), Molecular Pharmacology (D.F.V., A.L.R., C.M.N., P.J.C.), and Behavioral Pharmacology (C.K.J.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Chemistry, Vanderbilt University, Nashville, Tennessee (D.S.); and Preclinical Development (R.S.-P., M.M.C., R.R.), Seaside Therapeutics, Inc., Cambridge, Massachusetts
P. Jeffrey Conn
Drug Metabolism and Pharmacokinetics (R.D.M., A.L.B., F.W.B., T.S.S., T.M.B., K.A.B., J.S.D.), Medicinal Chemistry (A.S.F., J.M., B.S.B., C.W.L., K.A.E.), Molecular Pharmacology (D.F.V., A.L.R., C.M.N., P.J.C.), and Behavioral Pharmacology (C.K.J.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Chemistry, Vanderbilt University, Nashville, Tennessee (D.S.); and Preclinical Development (R.S.-P., M.M.C., R.R.), Seaside Therapeutics, Inc., Cambridge, Massachusetts
Craig W. Lindsley
Drug Metabolism and Pharmacokinetics (R.D.M., A.L.B., F.W.B., T.S.S., T.M.B., K.A.B., J.S.D.), Medicinal Chemistry (A.S.F., J.M., B.S.B., C.W.L., K.A.E.), Molecular Pharmacology (D.F.V., A.L.R., C.M.N., P.J.C.), and Behavioral Pharmacology (C.K.J.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Chemistry, Vanderbilt University, Nashville, Tennessee (D.S.); and Preclinical Development (R.S.-P., M.M.C., R.R.), Seaside Therapeutics, Inc., Cambridge, Massachusetts
Kyle A. Emmitte
Drug Metabolism and Pharmacokinetics (R.D.M., A.L.B., F.W.B., T.S.S., T.M.B., K.A.B., J.S.D.), Medicinal Chemistry (A.S.F., J.M., B.S.B., C.W.L., K.A.E.), Molecular Pharmacology (D.F.V., A.L.R., C.M.N., P.J.C.), and Behavioral Pharmacology (C.K.J.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Chemistry, Vanderbilt University, Nashville, Tennessee (D.S.); and Preclinical Development (R.S.-P., M.M.C., R.R.), Seaside Therapeutics, Inc., Cambridge, Massachusetts
J. Scott Daniels
Drug Metabolism and Pharmacokinetics (R.D.M., A.L.B., F.W.B., T.S.S., T.M.B., K.A.B., J.S.D.), Medicinal Chemistry (A.S.F., J.M., B.S.B., C.W.L., K.A.E.), Molecular Pharmacology (D.F.V., A.L.R., C.M.N., P.J.C.), and Behavioral Pharmacology (C.K.J.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Chemistry, Vanderbilt University, Nashville, Tennessee (D.S.); and Preclinical Development (R.S.-P., M.M.C., R.R.), Seaside Therapeutics, Inc., Cambridge, Massachusetts
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleArticle
DUAL MOLYBDENUM HYDROXYLASE METABOLISM OF PYRIMIDINE ANALOG
Ryan D. Morrison, Anna L. Blobaum, Frank W. Byers, Tammy S. Santomango, Thomas M. Bridges, Donald Stec, Katrina A. Brewer, Raymundo Sanchez-Ponce, Melany M. Corlew, Roger Rush, Andrew S. Felts, Jason Manka, Brittney S. Bates, Daryl F. Venable, Alice L. Rodriguez, Carrie K. Jones, Colleen M. Niswender, P. Jeffrey Conn, Craig W. Lindsley, Kyle A. Emmitte and J. Scott Daniels
Drug Metabolism and Disposition September 1, 2012, 40 (9) 1834-1845; DOI: https://doi.org/10.1124/dmd.112.046136
Research ArticleArticle
DUAL MOLYBDENUM HYDROXYLASE METABOLISM OF PYRIMIDINE ANALOG
Ryan D. Morrison, Anna L. Blobaum, Frank W. Byers, Tammy S. Santomango, Thomas M. Bridges, Donald Stec, Katrina A. Brewer, Raymundo Sanchez-Ponce, Melany M. Corlew, Roger Rush, Andrew S. Felts, Jason Manka, Brittney S. Bates, Daryl F. Venable, Alice L. Rodriguez, Carrie K. Jones, Colleen M. Niswender, P. Jeffrey Conn, Craig W. Lindsley, Kyle A. Emmitte and J. Scott Daniels
Drug Metabolism and Disposition September 1, 2012, 40 (9) 1834-1845; DOI: https://doi.org/10.1124/dmd.112.046136
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement